[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340214-105":59,"doc-detail-340214-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","stabilization-of-rrbp1-mrna-via-an-m6a-dependent-manner-in-prostate-cancer-constitutes-a-therapeutic-vulnerability-amenable-to-small-peptide-inhibition-of-mettl3","Stabilization of RRBP1 mRNA via an m6A-dependent manner in prostate cancer constitutes a therapeutic vulnerability amenable to small-peptide inhibition of METTL3","","Mounting evidence links METTL3-catalyzed m6A RNA methylation to diverse physiological and pathological processes, including tumorigenesis. The m6A landscape and METTL3 molecular mechanism in prostate cancer (PCa) remain unclear. The study shows METTL3 overexpression in PCa and association with poorer survival. METTL3 acts as an oncoprotein requiring its m6A enzymatic activity in AR+ and AR− cells.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/stabilization-of-rrbp1-mrna-via-an-m6a-dependent-manner-in-prostate-cancer-constitutes-a-therapeutic-vulnerability-amenable-to-small-peptide-inhibition-of-mettl3/340214/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/stabilization-of-rrbp1-mrna-via-an-m6a-dependent-manner-in-prostate-cancer-constitutes-a-therapeutic-vulnerability-amenable-to-small-peptide-inhibition-of-mettl3/340214.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does METTL3 influence prostate cancer progression?","Question",{"text":112,"@type":113},"METTL3 is overexpressed in prostate cancer and correlates with worse patient survival. Functional evidence shows METTL3 promotes oncogenic behavior through its m6A enzymatic activity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role does m6A play in METTL3’s regulation of RRBP1?",{"text":117,"@type":113},"METTL3 directly targets RRBP1, and METTL3 stabilizes RRBP1 mRNA in an m6A-dependent manner. This RRBP1 link is associated with aggressive traits in prostate cancer cells.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapeutic strategy is proposed in the study?",{"text":121,"@type":113},"The work develops two potential METTL3 peptide inhibitors (RM3 and RSM3) based on METTL3–METTL14 protein-protein interaction. These peptides suppress cancer cell proliferation in vitro and tumor growth in vivo.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340214,1790115033,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Cellular and Molecular Life Sciences (2024) 81:414  \n[https://doi.org/10.1007/s00018-024-05418-6](https://doi.org/10.1007/s00018-024-05418-6) Cellular and Molecular Life Sciences  \nORIGINAL ARTICLE  \nStabilization of RRBP1 mRNA via an m6A-dependent manner in prostate cancer constitutes a therapeutic vulnerability amenable to small-peptide inhibition of METTL3  \nYuqing Feng1,2,3 · Zenghui Li2,4 · Jinwei Zhu2,3 · Cheng Zou2,3 · Yu Tian2 · Jiangling Xiong2 · Qinju He2 · Wenjun Li2 · Hao Xu5 · Lu Liu2 · Bin Xu6 · Junfeng Shi1,2,3,4 · Dingxiao Zhang1,2,3  \nReceived: 27 March 2024 / Revised: 27 July 2024 / Accepted: 19 August 2024 © The Author(s) 2024  \nAbstract  \nMounting evidence has implicated the RNA m6A methylation catalyzed by METTL3 in a wide range of physiological and pathological processes, including tumorigenesis. The detailed m6A landscape and molecular mechanism of METTL3 in prostate cancer (PCa) remains ill-defined. We find that METTL3 is overexpressed in PCa and correlates with worse patient survival. Functional studies establish METTL3 as an oncoprotein dependent on its m6A enzymatic activity in both AR+ and AR − PCa cells. To dissect the regulatory network of m6A pathway in PCa, we map the m6A landscape in clinical tumor samples using m6A-seq and identify genome-wide METTL3-binding transcripts via RIP-seq. Mechanistically, we discover RRBP1 as a direct METTL3 target in which METTL3 stabilizes RRBP1 mRNA in an m6A-dependent manner. RRBP1 positively correlates with METTL3 expression in PCa cohorts and exerts an oncogenic role in aggressive PCa cells. Leveraging the 3D structural protein-protein interaction between METTL3 and METTL14, we successfully develop two potential METTL3 peptide inhibitors (RM3 and RSM3) that effectively suppress cancer cell proliferation in vitro and tumor growth in vivo. Collectively, our study reveals a novel METTL3/m6A/RRBP1 axis in enhancing aggressive traits of PCa, which can be therapeutically targeted by small-peptide METTL3 antagonists.  \nKeywords Prostate cancer · METTL3 · Peptide inhibitor · m6A · RRBP1  \nYuqing Feng and Zenghui Li contributed equally to this work.  \n􀀍 Junfeng Shi [Jeff-shi@hnu.edu.cn](Jeff-shi@hnu.edu.cn)  \n􀀍 Dingxiao Zhang [zdx1980@hnu.edu.cn](zdx1980@hnu.edu.cn)  \n1 Affiliated Hospital of Hunan University, School of Biomedical Sciences, Hunan University, Changsha, China  \n2 Hunan Key Laboratory of Animal Models and Molecular Medicine, School of Biomedical Sciences, Hunan University, Changsha, Hunan Province 410082, China  \n3 Shenzhen Research Institute, Hunan University, Shenzhen 518000, China  \n4 Greater Bay Area Institute for Innovation, Hunan University, Guangzhou 511300, China  \n5 Key Laboratory of Pesticides & Chemical Biology of Ministry of Education, College of Chemistry, Central China Normal University, Wuhan 430079, China  \n6 Department of Urology, School of Medicine, Affiliated Zhongda Hospital of Southeast University, Nanjing, Jiangsu Province 210009, China  \nIntroduction  \nProstate cancer (PCa) is a major cause of cancer-related deaths in men globally [1] . The treatment options are currently limited for advanced PCa patients, and androgen deprivation therapy (ADT) is the mainstay of therapy. Unfortunately, ADT usually fails to endow a durable response and most patients eventually develop castrationresistant PCa (CRPC), which is currently incurable [2] . Therefore, development of new therapeutics for aggressive PCa variants, especially CRPC, is urgently needed. So far, our understanding of PCa progression is incomplete, warranting further detailed mechanistic studies.  \nN6-Methyladenosine (m6A) is the most prevalent internal modification for eukaryotic RNA and influences nearly every stage of RNA metabolism, including transcription, splicing, decay, export and translation [3, 4] . As a dynamic and reversible process, m6A modification is decorated by Writer complex (i.e., methyltransferase including mainly  \n1 3  \nMETTL3, METTL14 and WTAP), removed by Er","cbCaikNKr1dSXmOm","https://ap.wps.com/l/cbCaikNKr1dSXmOm","pdf",12025682,18,"English","# Abstract\n## Introduction","[{\"question\":\"How does METTL3 influence prostate cancer progression?\",\"answer\":\"METTL3 is overexpressed in prostate cancer and correlates with worse patient survival. Functional evidence shows METTL3 promotes oncogenic behavior through its m6A enzymatic activity.\"},{\"question\":\"What role does m6A play in METTL3’s regulation of RRBP1?\",\"answer\":\"METTL3 directly targets RRBP1, and METTL3 stabilizes RRBP1 mRNA in an m6A-dependent manner. This RRBP1 link is associated with aggressive traits in prostate cancer cells.\"},{\"question\":\"What therapeutic strategy is proposed in the study?\",\"answer\":\"The work develops two potential METTL3 peptide inhibitors (RM3 and RSM3) based on METTL3–METTL14 protein-protein interaction. These peptides suppress cancer cell proliferation in vitro and tumor growth in vivo.\"}]","Stabilization of RRBP1 mRNA via an m6A-dependent manner in prostate cancer constitutes a therapeutic vulnerability amenable to small-peptide inhibition of METTL3 | PDF",1790034977,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/716e2b23bfb71a61f4e95a0cc195b612.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b0655175439ec47f3f4a0d3cff22e769.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e9f75c464b39f9a6836b26fbcb5f77d.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7aa113297972af9ae1b087fe5323081f.webp",980,1301]